Focus on Technology: Ortho Market Rockets and Stents Hold Steady

Originally Published MDDI December 2005   2005 MEDTECH SNAPSHOT

December 1, 2005

2 Min Read
Focus on Technology: Ortho Market Rockets and Stents Hold Steady

Originally Published MDDI December 2005

 

2005 MEDTECH SNAPSHOT

While the coronary stent market plateaus, the orthopedic industry is expecting record growth. Companies seem to be putting endless R&D and regulatory energy into this segment. According to Frost & Sullivan, devices and procedures for reconstruction, especially for hips and knees, are dominating the industry.
Financial management firm Merrill Lynch points to several top companies that are scheduled to gain FDA approval for artificial disks within the next few years. Spinal products and procedures, along with orthobiologicals and bone grafts, could quickly surpass other segments of the orthopedic industry.

Coronary stent market

During the third quarter of 2005, companies in the U.S. drug-eluting stent market reported sales growth of just 3%, according to Merrill Lynch. Industry estimates indicate that the $3.5 billion U.S. market will remain steady through 2009.

mddi0512p36a.jpg

The U.S. coronary stent market percentage shares for leading companies. Figures for 2005–2009 are estimated. Source: Merrill Lynch.

mddi0512p36b.jpg

Market share for bone grafts and orthobiologicals. The total market was approximately $804 million in 2004 and is estimated to reach $1.627 billion by 2008. Source: Merrill Lynch.

mddi0512p38a.jpg

Revenue projections for companies in the arthroscopy market (in $ millions). Numbers for 2005–2008 are estimated. Source: Merrill Lynch.

mddi0512p38b.jpg

Revenue projections for leading companies in the reconstructive orthopedic market (in $ millions). Numbers for 2005–2008 are estimated. Source: Merrill Lynch.

mddi0512p38c.jpg

Revenues for the bone stimulation market (in $ millions) are estimated for 2005–2008. Source: Merrill Lynch.

mddi0512p38d.jpg

Projected revenues (in $ millions) for the spinal market, 2005–2008. Figures do not include orthobiologicals. Source: Merrill Lynch.

Copyright ©2005 Medical Device & Diagnostic Industry

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like

Editors' Choice

Cardiovascular
Edwards Isn’t Sweating the SMART Results
Edwards Executives Weigh in on SMART Trial Results

Apr 26, 2024

M&A
A New Vision for Pixium’s Retinal Implants
Science Corporation to Acquire Pixium's Retinal Implants

Apr 26, 2024

FDA approved Boston Scientific's Farapulse system in January for pulsed field ablation treatment of atrial fibrillation.
Cardiovascular
Boston Scientific's Farapulse Is a Showstopper
Boston Scientific's Farapulse Is a Showstopper

Apr 25, 2024

Recent Headlines